Publication Highlights

Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease.  Steinman L, Patarca R, Haseltine W.  J. Exp. Med. 2023; 220(2): e20221322.

Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.  Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJ, Platten M, Garcia KC, Steinman L, Robinson WH.  Nature. 2022; 603(7900):321-327.

Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics.  Steinman JB, Lum FM, Ho PP, Kaminski N, Steinman L.  Proc. Nat. Acad. Sci. USA.  2020, OCT 6: 117(40):24620-24626.. 

Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy for Duchenne dystrophy.  Ho PP, Lahey LJ, Mourkioti F, Kraft PE, Filareto A, Brandt M, Magnusson KEG, Finn EE, Chamberlain JS, Robinson WH, Blau HM, Steinman L.  Proc. Nat. Acad. Sci. USA.  2018; Sep 25; 115(39):E9182-E9191.

Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine.  Rothbard JB, Rothbard JJ, Soares L, Fathman CG, Steinman L.  Proc. Nat. Acad. Sci. USA.  2018; Jul 3, 115(27):7081-7086.

Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models.  Ajami A, Samusik N, Wieghofer P, Ho PP, Crotti A, Bjornson Z, Prinz M, Fantl WJ, Nolan GP, Steinman L.  Nat. Neurosci. 2018; Apr; 21(4):541-551.

Time Correlation between mononucleosis and initial symptoms of MS.  Endriz J, Ho PP, Steinman L.  Neurol, Neuroimmunol,  Neuroinflamm.  2017; Feb 27, 4(3):e308.

A Journey in Science: The Privilege of Exploring the Brain and the Immune System.  Steinman L.   Mol Med.  2016; Jun 2:22.

Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Ho PP, and Steinman L.  Proc. Nat. Acad. Sci. 2016; 113(6): 1600-1605.

Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease. Kurnellas MP, Ghosn EE, Schartner JM, Baker J, Rothbard JJ, Negrin RS, Herzenberg LA, Fathman CG, Steinman L, Rothbard JB. Proc. Nat. Acad. Sci. USA. 2015; 112 (49): 15016-15023

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, Julkunen I, Vuorela A, Vaarala O, Nohynek H, Pasini FL, Montomoli E, Trombeta C, Adams CM, Rothbard J, Steinman L.  Sci Transl Med.  2015; 7, 294ra105.

No Quiet Surrender: Molecular Guardians In Multiple Sclerosis Brain. Steinman L.  J. Clin Invest.  2015; 125:1371-1378.

Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. Kurnellas, M. P., Schartner, J. M., Fathman, C. G., Jagger, A., Steinman, L., Rothbard, J. B. J. Exp. Med. 2014; 211 (9): 1847-1856.

Immunology of Relapse and Remission in Multiple Sclerosis.  Steinman L.  Ann Rev Immunol.  2014; 32:257-281.

Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes.  Roep BO, Solvason N, Gottlieb PA, Abreu JR, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H; BHT-3021 Investigators, Steinman L.   Sci Transl Med. 2013; Jun 26;5(191):191ra82.

Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Kurnellas MP, Adams CM, Sobel RA, Steinman L, Rothbard JB.  Sci Transl Med. 2013; Apr 3;5(179):179ra42

The Gender Gap in Multiple Sclerosis: Intersection of Science and Society.  Dunn SE, Steinman L.  JAMA Neurol. 2013; Mar 4:1-2.

A Tip leads cytotoxic T cells to the crime scene in neuroinflammation.  Steinman L.   Nat Immunol. 2013; Feb 15;14(3):196-7.

Weighing In On Autoimmune Disease: 'Hub-and-spoke' T cell traffic in autoimmunity.  Steinman L.   Nat Med. 2013; Feb;19(2):139-41.

Inflammatory cytokines at the summits of pathological signal cascades in brain diseases.  Steinman L.   Sci Signal. 2013; Jan 15;6(258):pe3.

Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011.  Steinman L, Axtell RC, Barbieri D, Bhat R, Brownell SE, de Jong BA, Dunn SE, Grant JL, Han MH, Ho PP, Kuipers HF, Kurnellas MP, Ousman SS, Rothbard JB.  Mult Scler. 2013; Jan;19(1):5-14.

Natalizumab: bench to bedside and beyond.  Rudick R, Polman C, Clifford D, Miller D, Steinman L.  JAMA Neurol. 2013; Feb 1;70(2):172-82.

The discovery of natalizumab, a potent therapeutic for multiple sclerosis.  Steinman, L.   J Cell Biol.  2012; Oct 29;199(3):413-6.

Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitis.  Kurnellas MP, Brownell SE, Su L, Malkovskiy AV, Rajadas J, Dolganov G, Chopra S, Schoolnik GK, Sobel RA, Webster J, Ousman SS, Becker RA, Steinman L, Rothbard JB.   J Biol Chem. 2012; Oct 19;287(43):36423-34.

Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.  Grant JL, Ghosn EE, Axtell RC, Herges K, Kuipers HF, Woodling NS, Andreasson K, Herzenberg LA, Herzenberg LA, Steinman L.  Sci Transl Med. 2012; Aug 1;4(145):145ra105.

Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice.  Han MH, Lundgren DH, Jaiswal S, Chao M, Graham KL, Garris CS, Axtell RC, Ho PP, Lock CB, Woodard JI, Brownell SE, Zoudilova M, Hunt JF, Baranzini SE, Butcher EC, Raine CS, Sobel RA, Han DK, Weissman I, Steinman L.   J Exp Med. 2012; Jul 2; 209(7):1325-34.  

Nostalgia: the similarities between immunological and neurological memory.  Steinman L.   Immunol Rev. 2012; Jul;248(1):5-9. 

Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation.  Ho PP, Kanter JL, Johnson AM, Srinagesh HK, Chang EJ, Purdy TM, van Haren K, Wikoff WR, Kind T, Khademi M, Matloff LY, Narayana S, Hur EM, Lindstrom TM, He Z, Fiehn O, Olsson T, Han X, Han MH, Steinman L, Robinson WH.   Sci Transl Med. 2012; Jun 6;4(137):137ra73.

Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein.  Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, Maini A, Han MH, Killestein J, Polman C, Goodyear AL, Dunn J, Steinman L, Axtell RC.   Mult Scler.  2012; Apr18(4):398-408.

Therapeutic Effects of Systemic Administration of Chaperone alpha B-Crystallin Associated with Binding Proinflammatory Plasma Proteins.  Rothbard JB, Kurnellas MP, Brownell S, Adams CM, Su L, Axtell RC, Chen R, Fathman CG, Robinson WH, Steinman L.   J Biol Chem. 2012; 287(13):9708-21.

Chaperone activity of alpha B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis.  Rothbard JB, Zhao X, Sharpe O, Strohman MJ, Kurnellas M, Mellins ED, Robinson WH, Steinman L.  J Immunol. 2011; 186 (7): 4263-8.

Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity.   Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, Johnson A, Nguyen K, Mukundan L, Moshkova M, Dugas JC, Chawla, A, Steinman, L.   J Exp Med.  2010; Aug 2:207(8):15991608.

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.  Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C.   Nat Med. 2010; 16 (4): 406-12.

Inhibitory role for GABA in autoimmune inflammation.  Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, Steinman L.   Proc Natl Acad Sci U S A. 2010; 107 (6): 2580-5.

Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity.  Steinman L.   J Intern Med. 2010; 267 (5): 441-51.

Innate and adaptive autoimmunity directed to the central nervous system.  Bhat R, Steinman L.  Neuron. 2009; 64 (1): 123-32.

Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L.  Proc Natl Acad Sci U S A. 2009; 106 (35): 14948-53.

A molecular trio in relapse and remission in multiple sclerosis.  Steinman L.  Nat Rev Immunol. 2009; 9 (6): 440-7.

Nuanced roles of cytokines in three major human brain disorders.  Steinman L.  J Clin Invest. 2008; 118 (11): 3557-63.

Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites.  Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H.  J Immunol. 2008; 181 (12): 8298-307.

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.  Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L.  Ann Neurol. 2008; 63 (5): 611-20.

Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.  Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L.  Nature. 2008; 451 (7182): 1076-81

A rush to judgment on Th17.  Steinman L.  J Exp Med. 2008; 205 (7): 1517-22.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.  Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.   Arch Neurol. 2007; 64 (10): 1407-15.

Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.  Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, Sobel RA, Robinson WH, Steinman L.  Nature. 2007; 448 (7152): 474-9.

Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity.  Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, Crowell A, Loh J, Oksenberg J, Steinman L.  J Exp Med. 2007; 204 (2): 321-30.

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.  Steinman L,  Nat Med. 2007; 13 (2): 139-45.

Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L.  Nat Immunol. 2007; 8 (1): 74-83.

What went wrong in the natalizumab trials?  Langer-Gould A, Steinman L.   Lancet. 2006; 367 (9512): 708-10.

Lipid microarrays identify key mediators of autoimmune brain inflammation.  Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH.  Nat Med. 2006; 12 (1): 138-43.

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.  Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L.  J Exp Med. 2006; 203 (2): 401-12.

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite.  Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L.  Science. 2005; 310 (5749): 850-5.

Design of effective immunotherapy for human autoimmunity.  Feldmann M, Steinman L.  Nature. 2005; 435 (7042): 612-9.

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.  Steinman L.  Nat Rev Drug Discov. 2005; 4 (6): 510-8.

  •